T-Liven PR™ 

T-Liven product shot
Price: $694

Evaluate HPL


T-Liven PR™ is a T-Cell validated pooled Human Platelet Lysate (hPL) shown to generate high potential CAR-T Cells.* for treatment and cart therapy.

This product is released against a T-cell growth clonal expansion performance assay and supports manufacture of CAR-T cells. T-Liven PR is offered in bag format and in customizable volumes. Available as 100ml off-the-shelf bag, T-Liven PR can also be filled to meet user volume specifications, negating the need to aliquot in house. Multiple packaging options, including bag size and input/outlet tubing, can also be selected to best meet processing needs for CAR T therapy.


  • Proprietary E-Beam irradiation process
  • Increased expansion of CAR T Cells
  • Increased percentages of naïve and central memory CAR T Cell phenotypes compared with AB Serum or FBS
  • Highly consistent across lots allowing for reproducible manufacturing of cell products
  • Performance in both 2D and 3D culture systems
  • Improved transduction efficiency compared with AB Serum


  • Manufactured under a certified ISO9001:2015 Quality Management System
  • Certificate of Analysis Documenting testing for Sterility, Endotoxin, Mycoplasma
  • CAR T-Cell growth verification assay
  • Certificates of Origin and Compliance available
  • Sexton Biotechnologies supports regulatory filings and audits of the process or facility


  • U.S. FDA DMF, meets PMDA and EU expectations for use in clinical manufacturing 
  • Manufactured from expired apheresis platelet units sourced from AABB-accredited and FDA-registered blood centres
  • Raw materials meet FDA and AABB requirements for platelet transfusion
  • Full donor traceability
  • TSE Statements, COC and Non-animal component statements available
  • *Torres-Chavez et al J. Im. Th. Cancer (2019)7.330